Skip to main content
SpringerLink
Log in

Other Biological Therapies in Primary Sjögren’s Syndrome

  • Chapter
  • First Online:
Sjögren’s Syndrome

  • 1205 Accesses

Abstract

Sjögren’s syndrome (SS) is a systemic autoimmune disease that mainly affects the exocrine glands and usually presents as persistent dryness of the mouth and eyes. SS typically affects white perimenopausal women, with an incidence of 4–5 cases per 100,000. At present, there is no treatment capable of modifying the evolution of SS and the therapeutic approach is based on symptomatic replacement or stimulation of glandular secretions, using substitutive and oral muscarinic agents. Extraglandular involvement requires organ-specific therapy generally based upon some combination of glucocorticoids and immunosuppressive agents, similar to that applied in patients with systemic lupus erythematosus (SLE) [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA. 2010;304:452–60.

    Article  PubMed  CAS  Google Scholar 

  2. Ramos-Casals M, Brito-Zerón P. Emerging biological therapies in primary Sjögren’s syndrome. Rheumatology (Oxford). 2007;46:1389–96.

    Article  CAS  Google Scholar 

  3. Ramos-Casals M, Font J. Primary Sjögren’s syndrome: current and emergent aetiopathogenic concepts. Rheumatology (Oxford). 2005;44:1354–67.

    Article  CAS  Google Scholar 

  4. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren’s syndrome: a pilot study. Arthritis Rheum. 2001;44:2371–5.

    Article  PubMed  CAS  Google Scholar 

  5. Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjögren’s syndrome: one-year followup. Arthritis Rheum. 2002;46:3301–3.

    Article  PubMed  CAS  Google Scholar 

  6. Caroyer JM, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjögren’s syndrome. Neurology. 2002;59:1113–4.

    PubMed  Google Scholar 

  7. Pessler F, Monash B, Rettig P, Forbes B, Kreiger PA, Cron RQ. Sjogren syndrome in a child: favorable response of the arthritis to TNFalpha blockade. Clin Rheumatol. 2006;25:746–8.

    Article  PubMed  CAS  Google Scholar 

  8. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270–6.

    Article  PubMed  CAS  Google Scholar 

  9. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–5.

    Article  PubMed  CAS  Google Scholar 

  10. Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjögren’s syndrome: a pilot study. J Rheumatol. 2004;31:96–101.

    PubMed  CAS  Google Scholar 

  11. Moutsopoulos NM, Katsifis GE, Angelov N, Leakan RA, Sankar V, Pillemer S, et al. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis. 2008;67:1437–43.

    Article  PubMed  CAS  Google Scholar 

  12. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sjögren’s syndrome treated with etanercept. Arthritis Rheum. 2007;56:3995–4004.

    Article  PubMed  CAS  Google Scholar 

  13. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjögren’s syndrome. J Autoimmun. 2010;35(2):225–31. PubMed PMID:20674271.

    Article  PubMed  CAS  Google Scholar 

  14. Mariette X, Gottenberg JE. Pathogenesis of Sjögren’s syndrome and therapeutic consequences. Curr Opin Rheumatol. 2010;22:471–7.

    Article  PubMed  CAS  Google Scholar 

  15. Miceli-Richard C, Gestermann N, Ittah M, et al. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren’s syndrome. Arthritis Rheum. 2009;60:1991–7.

    Article  PubMed  CAS  Google Scholar 

  16. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003;49:585–93.

    Article  PubMed  CAS  Google Scholar 

  17. Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB. Treatment of primary Sjögren’s syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res. 1999;19:943–51.

    Article  PubMed  CAS  Google Scholar 

  18. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren’s syndrome. J Interferon Cytokine Res. 1998;18:255–62.

    Article  PubMed  CAS  Google Scholar 

  19. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren’s syndrome: potential therapeutic targets. Ann Rheum Dis. 2010;69:945–8.

    Article  PubMed  CAS  Google Scholar 

  20. Smolen JS, Maini RN. Interleukin-6: a new therapeutic target. Arthritis Res Ther. 2006;8:407.

    Article  Google Scholar 

  21. Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000;43:1790–800.

    Article  PubMed  CAS  Google Scholar 

  22. Koenders MI, Joosten LA, van den Berg WB. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis. 2006;65 Suppl 3:iii29–33.

    Article  PubMed  Google Scholar 

  23. Isenberg D, Rahman A. Systemic lupus erythematosus – 2005 annus mirabilis? Nat Clin Pract Rheumatol. 2006;2:145–52.

    Article  PubMed  Google Scholar 

  24. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70:121–45.

    Article  PubMed  CAS  Google Scholar 

  25. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010;7:CD008331.

    Google Scholar 

  26. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69:976–86.

    Article  PubMed  CAS  Google Scholar 

  27. Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis. 2009;84(4 Suppl):14–24.

    PubMed  Google Scholar 

  28. Kuhn A, Luger TA. Psoriasis: is ustekinumab superior to etanercept for psoriasis? Nat Rev Rheumatol. 2010;6:500–1.

    Article  PubMed  CAS  Google Scholar 

  29. Vosters JL, Landek-Salgado MA, Yin H, et al. Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren’s syndrome. Arthritis Rheum. 2009;60:3633–41.

    Article  PubMed  CAS  Google Scholar 

  30. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM. Systemic and local interleukin-17 and linked cytokines associated with Sjögren’s syndrome immunopathogenesis. Am J Pathol. 2009;175:1167–77.

    Article  PubMed  CAS  Google Scholar 

  31. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren’s syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol. 2008;181:2898–906.

    PubMed  CAS  Google Scholar 

  32. Jois SD, Jining L, Nagarajarao LM. Targeting T cell adhesion molecules for drug design. Curr Pharm Des. 2006;12:2797–812.

    Article  PubMed  CAS  Google Scholar 

  33. Konttinen YT, Kasna-Ronkainen L. Sjögren’s syndrome: viewpoint on pathogenesis. One of the reasons I was never asked to write a textbook chapter on it. Scand J Rheumatol Suppl. 2002;116:15–22.

    Article  PubMed  Google Scholar 

  34. Mikulowska-Mennis A, Xu B, Berberian JM, Michie SA. Lymphocyte migration to inflamed lacrimal glands is mediated by vascular cell adhesion molecule-1/alpha(4)beta(1) integrin, peripheral node addressin/l-selectin, and lymphocyte function-associated antigen-1 adhesion pathways. Am J Pathol. 2001;159:671–81.

    Article  PubMed  CAS  Google Scholar 

  35. Bolstad AI, Eiken HG, Rosenlund B, Alarcon-Riquelme ME, Jonsson R. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren’s syndrome. Arthritis Rheum. 2003;48:174–85.

    Article  PubMed  CAS  Google Scholar 

  36. Papp KA, Henninger E. Evaluation of efalizumab using safe psoriasis control. BMC Dermatol. 2006;6:8.

    Article  PubMed  Google Scholar 

  37. Gadzia J, Turner J. Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab. J Drugs Dermatol. 2010;9(8):1005–9.

    PubMed  Google Scholar 

  38. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res. 2006;298:7–15.

    Article  PubMed  CAS  Google Scholar 

  39. Dunn LK, Feldman SR. Alefacept treatment for chronic plaque psoriasis. Skin Therapy Lett. 2010;15:1–3.

    PubMed  CAS  Google Scholar 

  40. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54:2807–16.

    Article  PubMed  CAS  Google Scholar 

  41. Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2010;37:234–45.

    Article  PubMed  CAS  Google Scholar 

  42. Hadj Kacem H, Kaddour N, Adyel FZ, Bahloul Z, Ayadi H. HLA-DQB1 CAR1/CAR2, TNFa IR2/IR4 and CTLA-4 polymorphisms in Tunisian patients with rheumatoid arthritis and Sjögren’s syndrome. Rheumatology (Oxford). 2001;40:1370–4.

    Article  CAS  Google Scholar 

  43. Downie-Doyle S, Bayat N, Rischmueller M, Lester S. Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjögren’s syndrome. Arthritis Rheum. 2006;54:2434–40.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    Pilar Brito-Zerón & Cándido Diaz-Lagares

  2. Department of Medicine, University of Cadiz, Department of Internal Medicine, Hospital Puerta del Mar, Cadiz, Spain

    M. Jose Soto-Cárdenas

  3. Spanish Group of Autoimmune Diseases (GEAS), Spanish Society of Internal Medicine (SEMI), Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Autoimmune Diseases, ICMD Hospital Clínic, Barcelona, Spain

    Manuel Ramos-Casals

  4. Lupus Research Unit, The Rayne Institute, King’s College London School of Medicine at Guy’s, King’s and St Thomas’ Hospitals, St Thomas’ Hospital, London, UK

    Munther A. Khamashta

Authors
  1. Pilar Brito-Zerón
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cándido Diaz-Lagares
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Jose Soto-Cárdenas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manuel Ramos-Casals
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Munther A. Khamashta
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Barcelona, Surgey, Hospital Clinic, Calle Villarroel, 170, Barcelona, 08036, Spain

    Manuel Ramos-Casals

  2. Massachusetts General Hospital, Boston, 02114, Massachusetts, USA

    John H. Stone

  3. National University of Athens, Athens, Greece

    Haralampos M. Moutsopoulos

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Brito-Zerón, P., Diaz-Lagares, C., Soto-Cárdenas, M.J., Ramos-Casals, M., Khamashta, M.A. (2011). Other Biological Therapies in Primary Sjögren’s Syndrome. In: Ramos-Casals, M., Stone, J., Moutsopoulos, H. (eds) Sjögren’s Syndrome. Springer, London. https://doi.org/10.1007/978-0-85729-947-5_41

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-947-5_41

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-946-8

  • Online ISBN: 978-0-85729-947-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation